Supernus to Present at Two Investor Conferences in September
ROCKVILLE, Md., Aug. 29, 2013 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals,
Inc. (Nasdaq:SUPN), a specialty pharmaceutical company, today announced that
the Company's management will present an overview of the Company at the
following investor conferences in September 2013:
Rodman & Renshaw:
Presentation Date: Monday, September 9
Time: 11:40am ET
Place: Millennium Broadway Hotel, NY
Stifel Nicolaus Weisel:
Presentation Date: Thursday, September 12
Place: Four Seasons Hotel, Boston, MA
About Supernus Pharmaceuticals, Inc.
Supernus Pharmaceuticals, Inc. is a specialty pharmaceutical company focused
on developing and commercializing products for the treatment of central
nervous system, or CNS, diseases. The Company has one marketed product for
epilepsy, Oxtellar XR™ (extended-release oxcarbazepine), and one approved
product for epilepsy, Trokendi XR™ (extended-release topiramate). The Company
is also developing several product candidates in psychiatry to address large
market opportunities in ADHD, including ADHD patients with impulsive
aggression. These product candidates include SPN-810 for impulsive aggression
in ADHD and SPN-812 for ADHD.
CONTACT: Jack A. Khattar, President and CEO
Gregory S. Patrick, Vice President and CFO
Supernus Pharmaceuticals, Inc.
Tel: (301) 838-2591
Press spacebar to pause and continue. Press esc to stop.